Document is current
Any future updates will be listed below
-
Authors
Luo, Laisheng
Ji, Yingjie
Yu, Lou
Huang, Yu
Liang, Xiao
Graham, David Y.
-
Funding
Funding for this research was provided by:
the Shanghai Science and Technology Committee (19411970300)
- License Information
-
More Information
Article History
Received: 15 September 2019
Accepted: 27 January 2020
First Online: 4 February 2020
Compliance with Ethical Standards
:
: Hong Lu is a consultant for Takeda and Astrazeneka, proton pump inhibitors in relation to <i>H. pylori</i> infection treatment. Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center. Dr. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel <i>H. pylori</i> therapies and has received research support for culture of <i>H. pylori</i> and is the PI of an international study of the use of antimycobacterial therapy for Crohn’s disease. Other authors declare no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Renji Hospital and with the 1964 Declaration of Helsinki and its later amendments.
